Curcumin
(Synonyms: 姜黄素; Diferuloylmethane; Natural Yellow 3; Turmeric yellow) 目录号 : GC14787
A yellow pigment with diverse biological activities
Cas No.:458-37-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
|
Cell experiment: |
T47D breast cancer cell line is grown in RPMI 1640 supplemented with 10% FBS, 2 mg/mL sodium bicarbonate, 0.05 mg/mL penicillin G, 0.08 mg/mL streptomycin. Culture is maintained on plastic flask and incubated at 37°C in 5% CO2. After growing sufficient amount of cells, cytotoxic effect of silibinin and curcumin is studied by 24, 48 and 72 h MTT assays in which 1000 cell/well are cultivated in a 96 well plate. After 24 h incubation in 37°C with humidified atmosphere containing 5% CO2, the cells are treated with serial concentrations of curcumin (5, 10, 20, 30, 40, 50, 60, 80, 100 µM), silibinin (20, 40, 60, 80, 100, 120, 140, 180, 200 µM), and curcumin-silibinin mixture (each of them 5, 10, 20, 30, 40, 50, 60, 80, 100 µM) for 24, 48 and 72 h in the quadruplicate manner, in addition to cells with 200 μL culture medium containing 10% DMSO for control. After incubation, the medium of all wells of the plate are exchanged with fresh medium and the cells are leaved for 24 h in incubator. Then, medium of all wells are removed carefully and 50 μL of 2 mg/mL MTT dissolved in PBS is added to each wells and the plate is covered with aluminum foil and incubated for 4.5 h again. After removing content of the wells, 200 μL pure DMSO is added to the wells. Then, 25 μL Sorensen’s glycine buffer is added and immediately absorbance of each wells is read in 570 nm using EL×800 Microplate Absorbance Reader with reference wavelength of 630 nm. |
|
Animal experiment: |
Curcumin (10 mg/kg), freshly suspended in saline, is administrated by oral gavage once a day for 3 weeks. Forty rats are randomLy assigned to 4 groups (n=10/each group): group I receives saline and serves as control, group II receives curcumin, group III is exposed to CMS andreceive saline and group IV are subjected to CMS andreceive curcumin. |
|
References: [1]. Gao S, et al. Curcumin attenuates arsenic-induced hepatic injuries and oxidative stress in experimental mice through activation of Nrf2 pathway, promotion of arsenic methylation and urinary excretion. Food Chem Toxicol. 2013 Jul 18. pii: S0278-6915(13)004 |
|
Curcumin is an inhibitor of tyrosinase with IC50 value of 47uM [1].
Curcumin is a natural compound with potency of anticancer. It is currently under clinical investigation for cancer chemoprevention. There is a variety of biochemical mechanisms of this anticancer function. The targets of Curcumin are involved in signaling pathways include transcription factors, growth factors,
inflammatory cytokines, receptors, and enzymes. Phase I trials have tested the toxicity and tolerability of Curcumin and found that Curcumin has no toxicities at doses up to 12 g/day. However, the bioavailability of Curcumin is quite poor. It is about ~1% after oral administration in phase I/II clinical trials and this hinders Curcumin‘s use in the clinic [2].
It is also reported that Curcumin reduces the generation of amloid beta (Aβ 40 and Aβ42) in SH-SY5Y neuroblastoma cells. It also down-regulates the expression of PS1 and GSK-3β in cells. All these cause the inhibition of Aβ formation and make Curcumin to be a potent therapeutic agent in AD [3].
References:
[1] Sachiko Shirota, Kouji Miyazaki, Ritsuo Aiyama, Minoru Ichioka and Teruo Yokokura. Tyrosinase inhibitors from crude drugs. Biol. Pharm. Bull. 1994, 17 (2): 266-269.
[2] Wungki Park, A.R.M Ruhul Amin, Zhuo Georgia Chen, and Dong M. Shin. New perspectives of curcumin in cancer prevention. Cancer Prev Res (Phila). 2013, 6(5): 387–400.
[3] Zhang Xiong, Zhang Hongmei, SiLu, LiYu. Curcumin mediates presenilin-1 activity to reduce β-amyloid production in a model of Alzheimer’s disease. Pharmacological Reports. 2013, 63: 1101-1108.
| Cas No. | 458-37-7 | SDF | |
| 别名 | 姜黄素; Diferuloylmethane; Natural Yellow 3; Turmeric yellow | ||
| 化学名 | (1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione | ||
| Canonical SMILES | COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC(=C(C=C2)O)OC)O | ||
| 分子式 | C21H20O6 | 分子量 | 368.38 |
| 溶解度 | ≥ 36.8 mg/mL in DMSO, ≥ 3.5 mg/mL in EtOH with ultrasonic and warming | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7146 mL | 13.5729 mL | 27.1459 mL |
| 5 mM | 0.5429 mL | 2.7146 mL | 5.4292 mL |
| 10 mM | 0.2715 mL | 1.3573 mL | 2.7146 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。